美国临床试验API接口数据_美国临床试验数据查询接口

概述
收录注册于美国的所有临床试验信息，涵盖临床试验基本信息、临床试验设计、患者招募信息、研究者信息、药物信息、适应症、临床研发阶段、临床试验状态以及临床试验结果等内容，目前收录信息约五十三万余条。
数据结构及样例
{
    "试验登记号": "NCT00000450",
    "登记日期": "2015-01-07",
    "其他试验登记号": ["NCI-2015-00712", "139511"],
    "试验标题":"Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma",
    "正式的科学名称": "A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard Carfilzomib, and High-dose Weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma",
    "国家/地区":  ["United States(美国)","Canada(加拿大)"],
    "开始日期": "2015-01-21",
    "首例受试者入组日期": "2015-01-07",
    "主要终点完成日期": "2021-10-14",
    "结束日期": "",
    "结果发布日期": "2025-01-01",
    "最近更新日期": "2025-05-01",
    "招募状态":["Active, not recruiting（试验进行中，但目前不招募）"],
    "注册机构": "美国",
    "申办单位": ["University of California San Francisco（美国加州大学旧金山分校）"],
    "合作方": ["Amgen Inc（安进）","Sanofi Inc（赛诺菲）"],
    "药品名称":["Variable regimens including carfilzomib","dexamethasone", "isatuximab(艾沙妥昔单抗)" , "isatuximab + carfilzomib + dexamethasone"],
    "干预信息": [{"名称":"isatuximab","干预类型":"生物药"},{"名称":"dexamethasone","干预类型":"药品"}，{"名称":"carfilzomib","干预类型":"药品"}],
    "靶点":  [{"全称":"CD38 Molecule（CD38）","简称":"CD38","中文":"环腺苷二磷酸核糖1","别名":["CD38 Antigen","ADPRC1","T10"],"详情":"https://www.uniprot.org/uniprotkb/P28907"}],
    "作用机制": ["ADP ribosyl cyclase-1 inhibitor（环腺苷二磷酸核糖1抑制剂）","Proteasome inhibitor（蛋白酶体抑制剂）","Ubiquitin inhibitor（泛素化抑制剂）"],
    "适应症": ["multiple myeloma（多发性骨髓瘤）"],
   "工艺技术": ["Biological（生物药）","Formulation powder（粉末制剂）","Freeze drying（冻干制剂）","Solution（溶液剂）","Subcutaneous formulation（皮下注射剂）"]，
    "治疗领域": ["癌症及其他肿瘤","心血管系统疾病","血液和淋巴系统疾病","免疫性疾病"],
    "试验阶段": ["Phase 1 Clinical（Ⅰ期）"],
    "试验类型": ["Interventional（干预性研究）"],
    "试验目标":["Treatment（治疗性）"],
    "干预类型": ["Biological（生物药）","Drug（药品）"],
    "干预分组方式": "随机化",
    "干预模型": "平行设计",
    "盲法": "单盲",
    "设盲对象": "结果评价人员",
    "观察模型": "",
    "观察时间点": "",
    "患者登记研究": "",
    "患者登记随访持续时间": "",
    "生物标本存放形式": ""，
    "生物标本说明": ""，
    "生物标记物作用": "Male and Female",
    "性别": "Male and Female"，
    "性别": "Male and Female",
    "终点类型":["Safety（安全性）","Efficacy（有效性）","Pharmacokinetics（药代动力学）","Pharmacodynamics（药效学）"] ,
    "主要终点指标": [{"指标":"Incidence of Dose-Limiting Toxicities (DLT)","评价时间":"Up to 60 days of the last dose of study drug","描述":"Treatment-related Adverse events resulting in a DLT will be summarized by maximum toxicity grade for each dose level of isatuximab."}],
    "次要终点指标": [{"指标":"Incidence of isatuximab-specific antidrug antibodies (ADA) ","评价时间":"Up to 1 year ","描述":"Analysis of Incidence of isatuximab-specific antidrug antibodies (ADA) to be performed by Sanofi-Oncology."}],
    "其他终点指标": [{"指标":" Overall survival (OS)","评价时间":"assessed at 1, 2, and 3 years from start of treatment","描述":" Duration of time from start of treatment to death on study from any cause,"}],
    "目标入组人数": "80",
    "实际入组人数": "83"，
    "年龄范围": "18 Years - No limit", 
    "性别": "Male and Female"，
    "是否接受健康受试者": "No",
    "入组期限": "110.39 Months"，
    "入组率": "0.75 Patients/Month",
    "联系人信息": [{"联系人类别":"试验联系人","姓名":"Clinical Trials Referral Office","联系方式":"mayrstudies@mmmn.edu"}], 
    "试验点信息": ["Princess Margaret Cancer Centre","Icahn School of Medicine at Mount Sinai","Colorado Blood Cancer Institute","University of California, San Francisco","Sarah Cannon Cancer Center","Hackensack University Medical Center"]，
    "临床试验结果": [{"结果名称":"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And&#x2F;Or Refractory Multiple Myeloma Patients","结果链接":"https://clinicaltrials.gov/study/NCT03275285?rank=3&tab=results"}],
    "试验文件": [{"文件名称":"Study Protocol","文件链接":"https://cdn.clinicaltrials.gov/large-docs/85/NCT03275285/Prot_002.pdf"}],
}